This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Crizanlizumab parenteral


Infusions of crizanlizumab.

These products have been produced by recombinant technology using Chinese Hamster Ovary (CHO) cell lines.

Drugs List

  • ADAKVEO 100mg/10ml concentrate for solution for infusion vial
  • crizanlizumab 100mg/10ml concentrate for solution for infusion vial
  • Therapeutic Indications


    Prevention of recurrent vaso-occlusive crises in sickle cell syndrome

    Prophylaxis of recurrent vaso-occlusive crises in sickle cell patients aged 16 years and older either alone or with hydroxyurea or hydroxycarbamide.



    5mg/kg administered over 30 minutes at week 0, week 2 and every 4 weeks thereafter.


    Children aged 16 years and older
    (See Dosage; Adult).

    Additional Dosage Information

    If crizanlizumab is administered within 2 weeks after the missed dose, continue dosing according to the patient's original schedule. However, if crizanlizumab is administered more than 2 weeks after the missed dose, dosing should be continued every 4 weeks thereafter.


    For intravenous infusion only.


    Children under 16 years

    Precautions and Warnings

    Severe renal impairment

    Advise patient ability to drive or operate machinery may be impaired
    Combination therapy: refer to information for concomitant agent
    Treatment to be prescribed under the supervision of a specialist
    Record name and batch number of administered product
    Monitor patient for infusion-associated reactions (IARs)
    May affect results of some laboratory tests
    Interrupt treatment if severe infusion reaction occurs
    Female: Ensure adequate contraception during treatment
    Advise patient to seek medical advice if delayed adverse event(s) occurs

    Pregnancy and Lactation


    Crizanlizumab is contraindicated during pregnancy.

    The manufacturer recommends crizanlizumab is not used in pregnancy and in women of childbearing potential not using contraception. At the time of writing, human data is limited but animal studies have shown crizanlizumab has the potential to cause foetal losses when administered to a pregnant woman.


    Crizanlizumab is contraindicated during breastfeeding.

    The manufacturer recommends that breastfeeding is discontinued during treatment with crizanlizumab. It is unknown if crizanlizumab is excreted in human milk but antibodies can be excreted in human milk. There are no data on the effects of crizanlizumab on the breast-fed infant or on milk production. A risk to neonates cannot be excluded.

    Side Effects

    Abdominal pain
    Back pain
    Chest pain
    Infusion related reaction
    Infusion site pain
    Infusion site reaction
    Oropharyngeal pain
    Swelling (injection site)
    Vulvovaginal itching

    Effects on Laboratory Tests

    Crizanlizumab has been shown to interfere with automated platelet counts (platelet clumping) in particular when tubes containing ethylenediaminetetraacetic acid (EDTA) have been used. This has led to unevaluable or falsely decreased platelet counts. To mitigate the potential for laboratory test interference, it is recommended to run the test within 4 hours of blood collection or use citrate tubes. Platelet counts can be estimated via a peripheral blood smear when needed.


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: October 2021

    Reference Sources

    Summary of Product Characteristics: Adakveo 10mg/ml concentrate for solution for infusion. Novartis Pharmaceuticals UK Ltd. Revised July 2021.

    NICE Evidence Services Available at: Last accessed: 19 October 2021

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.